trans-1-(4-Hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyrimidin-4-yl)imidazole

White solid. PROTECT FROM LIGHT. PACKAGED UNDER INERT GAS. A potent cell-permeable inhibitor of the a- and b-isoforms (IC₅₀ = 44 nM), but not the g- or d-isoform (IC₅₀ > 100 µM), of MAP kinase p38. It inhibits IL-1 and TNF-a production (IC₅₀ = 120 nM and 350 nM, respectively) in LPS-stimulated human peripheral blood monocytes. Also reduces brain injury and neurological deficits in cerebral focal ischemia and reduces myocardial reperfusion injury by reducing the expression of endothelial adhesion molecule and by blocking polymorphonuclear (PMN) leukocytes accumulation. Purity: ≥97% by HPLC.

Ref.: Gao, F., et al. 2002. Cardiovasc. Res. 53, 414. Ju, H., et al. 2002. J. Pharmacol. Exp. Ther. 301, 15. Legos, J.J., et al. 2002. Eur. J. Pharmacol. 447, 37. Barone, F.C., et al. 2001. J. Pharmacol. Exp. Ther. 296, 312. Ward, K.W., et al. 2001. Pharm. Res. 18, 1336. Underwood, D.C., et al. 2000. J. Pharmacol. Exp. Ther. 293, 281. Underwood, D.C., et al. 2000. Am. J. Physiol. Lung Cell Mol. Physiol. 279, L895.